CLRM-18 SCREEN FAILURES IN PHASE III GLIOBLASTOMA CLINICAL TRIALS

Glioblastoma (GBM) remains the most common and lethal malignant primary brain tumor in adult patients, with median overall survival ranging from 7 to 22 months. National Comprehensive Cancer Network guidelines encourage participation in clinical trials for both newly diagnosed and recurrent GBM pati...

Descripción completa

Detalles Bibliográficos
Autor principal: Peters, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354194/
http://dx.doi.org/10.1093/noajnl/vdac078.038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354194/
http://dx.doi.org/10.1093/noajnl/vdac078.038

Ejemplares similares